Admission to Trading on the OTCQB Venture Market in the United States
RNS & Investor News
Head of Quality & Operations appointment
08 October 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol and diabetes announces the appointment of
Aneta Zlotkowska as Head of Quality & Operations.
Aneta joins OptiBiotix from a position as Lead Development Manager at
Tesco Plc, one of the world's largest retailers of consumer goods where
her main responsibilities were within the distribution business unit in
logistics and operations. Prior to working for Tesco, Aneta was a
Quality Assurance and Purchasing Manager at Cornelius Group Plc where
she has also held the positions of Senior Supply Chain Executive and
Supply Chain Manager. Aneta holds a CIPS Diploma in Procurement and
Supply Chain Management and has completed HACCP and BRC Third Party
Auditor courses by the BRC Academy.
Dr. Fred Narbel, Managing Director of OptiBiotix's
prebiotics division, commented: "Given
OptiBiotix's rapid international expansion with the announcements of
various distribution and manufacturing agreements for SlimBiome®,
OptiBiome® and WellBiome® as well as commercial launches of finished
products containing OptiBiotix's technology in the UK (RNS: 7
January 2020) and the USA & Canada (RNS: 4 May 2020), we feel
the need to appoint a full-time employee with the relevant skillset
to manage and lead OptiBiotix's quality management system and
operations.
"Aneta will join the Company on 1 January 2021 and will work towards ensuring timely deliveries of high-quality ingredients to OptiBiotix's partners around the world. Moreover, Aneta is tasked with attaining a BRC certification for OptiBiotix Ltd."
OptiBiotix Health plc |
||
Stephen O'Hara, Chief Executive |
Contact via Walbrook below |
|
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
|
Anna Dunphy |
Mob: 07876 741 001 |
|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human
microbiome - the collective genome of the microbes in the body - in
order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements. More
than sixty international food and healthcare supplement companies have
signed agreements with OptiBiotix to incorporate their human microbiome
modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, diabetes, digestive health, and health and wellbeing. .
Latest Video
OptiBiotix Health PLC - Full Year Results Investor
Presentation
Group CEO Stephen O'Hara | July 2025
Latest Podcast
Stephen OHara interview with Investors
Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com